Patients and Methods:
The main outcomes of the study were the sample adequacy of each method to provide a final pathological diagnosis, and the concordance in diagnosis between core and FNA specimens. The secondary outcomes were the sensitivity and specificity of the findings for each needle and the incremental yield of using both needles compared with using each needle alone.
Results:
A total of 56 patients with 61 solid pancreatic lesions were evaluated. The mean number of passes with FNA was 3.5 (ranges 18) and with core biopsy needle was 1.7 (ranges 15). The proportions of adequate samples were 50/61 (81.9%) for FNA and 45/61 (73.8%) for core biopsy (P = 0.37). The diagnostic yield was 46/61 (75.4%), 42/61 (68.9%) and 47/61 (77.1%) for FNA, core, and both, respectively. There was a substantial agreement of 87.5% (κ = 0.77; P < 0.001) in the findings of core and FNA specimens. The sensitivity for the diagnosis of malignancy for FNA and core biopsy were 68.1% and 59.6%, respectively (P = no significant [NS] ). The specificity was 100% for both methods. The incremental increase in sensitivity and specificity by combining both methods are 1.5% and 0%, respectively.
Conclusion:
There are NS differences in the diagnostic yield between EUSguided 22gauge core biopsy and standard 25gauge FNA for diagnosing pancreatic lesions, but core biopsy required fewer numbers of passes. There 
INTRODUCTION
Endoscopic ultrasoundguided fineneedle aspiration (EUSFNA) has been shown to be a safe and highly accurate diagnostic modality for pancreatic masses. [1, 2] Real time assessment of cytopathology samples at the bedside increases diagnostic accuracy and efficiency of the procedure, [2, 3] but this setting is costly, time consuming and not widely available in routine clinical practice. [4] To offset some of these limitations, "TruCut" core needles have been developed to provide larger amounts of tissue with conserved architecture for better histological analysis. [5] However, compared to the conventional 22gauge FNA needle, the initial 19gauge core needle had a lower accuracy for diagnosing pancreatic lesions, [4, 6, 7] related to the limited flexibility of the needle especially in the setting of an angled scope in the duodenum. [6, 7, 8] [11] for which the use of the 25gauge FNA has increasingly become the standard. Moreover, it remains unknown if the diagnostic yield of EUSguided sampling can be improved by combining both standard FNA and core needles while sampling the same lesion.
We conducted the current study to compare the diagnostic yield of EUSguided 22gauge core needle biopsy to a 25gauge FNA in sampling the same pancreatic lesions during the same endoscopic procedure.
PATIENTS AND METHODS
We conducted a retrospective cohort study in patients with solid pancreatic lesions that were detected on crosssectional imaging. All patients underwent sampling of these lesions by both EUS guided 22gauge core biopsy (needle with a side fenestration) and 25gauge FNA during the same endoscopic procedure.
These procedures were performed by two endosonographers (KKP and DYS) during a 13 months period from May 2011 to June 2012 at two tertiary care centers in Houston, Texas. FNA and core biopsy specimens were read by a cytopathologist at both institutions. Bedside assessment of FNA tissue sample adequacy by a cytopathologist was available in only one of the two institutions. At the time of the study, it was our policy to routinely perform three to five passes with the two needles. We obtained information on followup for at least 6 months after the procedure by the last date of December 31, 2012. For patients without a cancer diagnosis on the initial EUSguided sampling by either needle, the final diagnosis was made either by surgical specimen when available or clinical followup in combination with imaging after at least 6 months from date of the procedure.
The main outcomes of the study were (a) the sample adequacy of each method to provide a final pathological diagnosis. Adequacy of the samples was determined from the pathologist's description of the specimen as either satisfactory or unsatisfactory to provide a definitive pathological diagnosis based on the https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4362000/?report=printable 3/9
Statistical analysis cellularity of the specimen on both the smear and cell block material, and (b) the concordance in diagnosis between the core needle and FNA specimens.
The secondary outcomes were the sensitivity and specificity for each needle, and the incremental yield of using each or both needles compared to using each needle alone. These were secondary aims because the gold standard (surgical specimen) was not available in all cases.
Information on adverse events was also obtained by reviewing the procedure reports for immediate complications and emergency room visits or hospitalizations for delayed complications.
Individual patients were the unit of analysis. The diagnostic yield was calculated as the percentage of all cases with adequate specimen diagnosed with malignant or nonmalignant pancreatic lesions by EUSguided sampling. The diagnostic yield could be malignant or nonmalignant. The sensitivity of any diagnostic modality in the study was calculated as the proportion of patients correctly diagnosed with malignant pancreatic lesions. The specificity was calculated as the proportion of patients correctly diagnosed with a nonmalignant tissue. The gold standard for sensitivity and specificity was the final diagnosis of malignant or nonmalignant pancreatic lesions by EUS, surgery, serial imaging and clinical evaluation during at least 6 months after EUS. The concordance between EUSguided tissue diagnosis by FNA and core needles was calculated using Lin's concordance coefficient to determine the positive agreement between the FNA and core biopsy samples. The Chisquare test was used to compare proportions, and the ttest was used to compare the number of needle passes between the two methods.
The Institutional Review Board of Baylor College of Medicine approved this study. Informed consent was obtained from all patients prior to EUS.
RESULTS
A total of 56 patients with 61 pancreatic lesions were analyzed [ Table 1 ]; 35 were male (57.4%), and the mean age was 61 years (ranges 2487). Four patients had two separate pancreatic lesions sampled during the same procedure, and one patient had the same lesion sampled during two separate procedures. The lesions were mostly located in the pancreatic head or body, but also in the uncinate process (n = 5), tail (n = 2), and peripancreatic lymph nodes (n = 6).
The proportions of adequate samples were 50/61 (81.9%) for FNA and 45/61 (73.8%) for core biopsy with no significant (NS) differences (P = 0.37). The mean number of passes with FNA was 3.5 (ranges 18), and the mean number of passes with the core biopsy needle was 1.7 (ranges 15) [ Table 2 ].
The diagnostic yield (malignant or nonmalignant) was 46/61 (75.4%), 42/61 (68.9%) and 47/61 (77.1%) for EUSguided FNA, EUSguided core, and both combined, respectively. There was a substantial agreement of 87.5% (ϰ = 0.77; P < 0.001) between the findings of the core biopsy and FNA.
The diagnostic yield for malignant lesions was 32/40 (80%), 28/40 (70%) and 32/40 (80%) for EUS guided FNA, EUSguided core, and both combined, respectively. The histopathologic diagnosis of these malignant lesions was adenocarcinoma (n = 22), neuroendocrine tumors (n = 5) and one each for squamous cell carcinoma, adenosquamous carcinoma, giant cell carcinoma, acinar cell carcinoma, and solid pseudopapillary carcinoma.
Fineneedle aspiration provided an incremental diagnostic yield in 4/47 (8.5%) (adenocarcinoma n = 3, atypical cells suspicious of malignancy n = 1) when core biopsy needle was not diagnostic. Conversely, the incremental diagnostic yield of core biopsy needle was 1/47 (2.1%); in that case core biopsy needle provided a diagnostic sample (normal pancreatic tissue) when FNA needle did not, on a patient who had a final diagnosis of focal pancreatitis. The incremental diagnostic yield observed by using information from both techniques was 5/47 (10.6%).
In eight cases both FNA and core missed a malignancy, diagnosis that was later made by surgical specimen resection or by clinical followup. These cases included Hodgkin lymphoma (n = 2), neuroendocrine tumor (n = 2) and pancreatic adenocarcinoma (n = 4). Therefore considering a gold standard that combined the diagnostic yield of both needles and clinical and radiological followup at least 6 months from date of the procedure, the sensitivity for diagnosing malignancy for FNA and core biopsy were 68.1% and 59.6%, respectively (P = NS). The specificity was 100% for both methods. The incremental increase in sensitivity and specificity by combining both methods during the same procedure are 1.5% and 0%, respectively.
Clinical followup in combination with imaging was performed after at least 6 months (mean 9.2; ranges 615 months) from the date of the procedure for these cases. The nonmalignant tissue diagnosis by EUS guided tissue sampling and the final clinicopathological diagnosis are shown in Table 3 .
DISCUSSION
This is the largest study to directly compare the diagnostic yield of EUSguided 22gauge core needle biopsy (needle with a side fenestration) with 25gauge standard FNA when sampling a pancreatic lesion during the same endoscopic procedure. There was a substantial agreement for sample adequacy and diagnostic yield between the findings of core biopsy and FNA, but with fewer passes with the core needle. The diagnostic yield and sensitivity were higher with FNA but not statistically significant. There was no incremental yield of using both needles compared to using each needle alone.
Giovannini et al., first evaluated this 22gauge core needle biopsy in 61 patients, reporting a 90% diagnostic yield, 87% sensitivity and 100% specificity. [12] Subsequent studies, most were published in abstract forms, comparing this 22gauge core needle biopsy with standard 22guage FNA showed a comparable or higher sensitivity in favor of the 22gauge core needle biopsy. [9, 13, 14, 15] Clearly, the 25 gauge FNA is likely to have a better diagnostic yield than the 22gauge FNA. [11] In our study of 25gauge FNA, the sample adequacy, diagnostic yield, sensitivity and specificity were at least similar between both methods and numerically higher for sensitivity and diagnostic yield.
We did not find meaningful incremental diagnostic yield when using both needles to sample the same pancreatic lesion during the same procedure when compared with each needle alone. This is consistent with a recent study by Cho et al. who evaluated the added diagnostic yield of sequential EUSguided 22 gauge core needle after failed adequate tissue sample by EUSguided FNA in 27 patients with mediastinal lesions. [17] Thus, combined use of both needles appears to the only increase cost with no added diagnostic benefit.
There are other factors in addition to the diagnostic yield, which appears to be similar, that are likely to determine the use of one needle over the other. The use of the onsite cytopathological evaluation increases the diagnostic yield of EUSguided FNA for the diagnosis of solid pancreatic lesions. [2, 3, 16] The use of core needles has the advantage of obviating the need for onsite cytopathologist, thus potentially reducing the cost, as well as the total time of the procedure. Furthermore, the reduction in the total number of passes has additional time sparing advantage. In our study, there was a lower number of passes between the core biopsy and FNA; 1.7 versus 3.5, respectively. We did not perform a formal cost analysis and we also did not examine survival as an outcome and, therefore, the costeffectiveness of these two techniques while likely to be comparable is not clear and much to be further examined.
One of the limitations of the core needle biopsy is the lack of technique standardization, and this may explain the inconsistency of the diagnostic yield with this method. Recently a study comparing three different techniques with this method:
1. Stylet is rapidly removed before 30 s of half suction (5 mL) is applied followed by five to and fro thrusts of the needle before withdrawal, 2. Similar to the first technique except full suction (10 mL) is applied, and 3. Capillary aspiration without suction is used, whereby the stylet is slowly removed over 40 s as the needle is moved to and fro; showed that the capillary biopsy method provided significantly higher tissue adequacy compared to half or full suction methods. [18] In this study, the core needle missed a diagnosis of malignancy in four cases that FNA had provided a malignant diagnosis. Three of these were lesions in the head of the pancreas. Although the 22gauge core needle was developed to offset the lack of flexibility of the 19gauge core needles when sampling lesions in the head of the pancreas, this limitation remains when compared to standard 25gauge FNA. While the difference did not reach statistical significance in our relatively small sample, their difference could be clinically meaningful. Future studies should further investigate their possible differences. A new 25gauge core needle has been introduced in the market and studies comparing the 22gauge versus 25gauge core needle are required.
Limitations of this study included a lack of information on the sequence of using the needles; it is possible that one needle can impact on the sample obtained by the second needle. Furthermore, the pathologist was not blinded to the samples done by either needle, which could have biased their final interpretation. Due to the retrospective design of the study, we cannot determine how many samples had visible cores when using the side fenestrated needle.
In summary, there was a high concordance between EUSguided 22gauge core biopsy and standard 25 gauge FNA for diagnosing pancreatic lesions. The sample adequacy was not different between the two techniques. There was a small, but not statistically significant incremental diagnostic yield with FNA, but core biopsy required fewer numbers of passes. However, there was no incremental diagnostic yield when using both needles to sample the same pancreatic lesion during the same procedure. Table 1 Characteristics of the study patients and their pancreatic lesions Table 2 Comparison of outcomes of the two procedures Table 3 Initial and final diagnoses on followup among 28 cases with EUSguided nonmalignant samples in either FNA or core
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